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The 12th International Conference on Screening for LungCancer, hosted by the Screening Committee of the Japan
Lung Cancer Society, was held in Nara, Japan on April 8–10,
2005. The International Early Lung Cancer Action Program
(I-ELCAP) has conducted regular conferences semiannually
both at Weil Cornell Medical College in New York, NY and
at other I-ELCAP sites in the world. This 12th conference
was a landmark of I-ELCAP activity for 6 years. Low-dose
computed tomographic (LD-CT) scan was experimentally
introduced for lung cancer screening in both Japan and the
United States in 1993. Commemorating the pioneering work
on LD-CT screening for lung cancer for a decade by both the
ELCAP and the Japanese group, this I-ELCAP conference
was hosted by the Screening Committee of the Japan Lung
Cancer Society under the auspices of the Japan Lung Cancer
Society, the Japanese Respiratory Society, the Japanese So-
ciety for Respiratory Surgery, the American Cancer Society,
and the International Association for Studies of Lung Cancer
(IASLC). The broadest mission of these conferences is the
collective pursuit of avant-garde understanding of the issues
surrounding screening for lung cancer, the broadest sub-
issues being early diagnosis and early intervention. Any
given conference focuses on issues that are of particular
interest at the time. As always, the conference provides an
update of research on and practice of screening for lung
cancer, including updates of I-ELCAP protocols and results
of research. For the conference, more than 180 attendees from
eight countries, including non-members of the I-ELCAP,
gathered in Nara, one of the ancient capitals of Japan in the
seventh to eighth century (Figure 1).
The 10th and 11th Conferences focused on the results
on the diagnostic performance of the I-ELCAP protocol for
CT screening and on alternatives to resection in early inter-
vention. These conferences also focused on the discussion
between individuals seeking screening and their physicians
such as the potential benefit of a single round of screening.
However, it requires the likelihood that early intervention
could cure such a cancer, and that the patient would avoid
death from another cause for a decade or another specified
period. The 12th International Conference aimed to summa-
rize the evaluation by I-ELCAP and Japanese groups as to the
benefit of CT screening for lung cancer.
CONSENSUS STATEMENT
This Nara conference addressed the two broad missions
of these conferences: advancement policy (relevant research
on early diagnosis of lung cancer) and translation of up-to-
date findings into guidelines for practice based on the accu-
mulated evidence from the I-ELCAP consortium. Experi-
ences with screening performed by individual institutions
were presented for the Japan Association against Lung Can-
cer (ALCA), Hitachi’s employee screening program, and the
Mayo Clinic screening program. The Japanese Lung Cancer
Screening Study (JLCSS) group reported on its nationally
based study comparing 46,733 people who had at least one
CT screening test with 91,970 people who had at least one
chest radiographic screening. I-ELCAP presented its data for
more than 28,000 people who have had more than 50,000
screenings. Thus, this conference reviewed the largest studies
ever conducted with CT screening for lung cancer.
The final results of the JLCSS will be reported in 2007,
but a 2005 interim report indicated that it will show a
reduction in deaths from lung cancer as a result of screening.
The I-ELCAP presented its approach to screening research,
development of the regimen and assessing its benefit, and
distinguishing between the screening’s diagnostic and prog-
nostic implications. Diagnostically, the concern centers on
how early the diagnosis of lung cancer can be achieved while
minimizing work-up, including biopsies. Relative to progno-
sis, the issue is the preventability of death from lung cancer
by early intervention based on early diagnosis. In the I-
ELCAP experience, more than 80% of diagnoses have been
achieved at stage I, with 90% of the biopsies resulting in a
diagnosis of malignancy. Critical in the regimen is the iden-
tification of growth consistent with malignancy. The I-
ELCAP also presented results pertaining to prognosis. These
confirm that screen-diagnosed lung cancers presenting as
solid nodules lead to death if not treated, whereas some cases
of adenocarcinoma presenting as a non-solid nodule may be
so slow-growing as to be unlikely to be fatal for a short time
if not treated. It is estimated that more than 80% of deaths
from lung cancer could be prevented by early intervention
under CT screening. The I-ELCAP also discussed competing
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causes of death in the highest-risk subcohort of people aged
60 to 75 years with at least 30 to 80 pack-years of smoking.
It found that the 5- and 10-year rates of death from causes
other than lung cancer (conditional on not dying from lung
cancer) were low, 3% and 7%, respectively.
I-ELCAP surgical and radiotherapy results were pre-
sented together with those of Japanese studies on limited
resection, transbronchoscopic brachytherapy, percutaneous
microwave and radiofrequency ablation, cryosurgery, heavy-
particle radiation therapy, and stereotactic radiation therapy.
Pathologic and molecular features of early cancer were also
presented. These results provided the foundation of new
treatment trials on screen-diagnosed lung cancers.
Three workshops were held. One of these focused on
the methodological advances and safety of CT-guided fine-
needle aspiration biopsy and issues of follow-up in biopsy-
negative cases central to a regimen of screening. Another
workshop focused on multicenter treatment trials, such as
different protocols depending on CT features of nodules and
the critical issues to be studied. The third workshop focused
on computer-aided detection and characterization to deal with
the increasing number of images per person that can now be
produced by a single CT scan.
ORAL PRESENTATIONS: CURRENT STATUS
AND EXPLORATORY STUDIES OF LUNG
CANCER SCREENING
Keiichi Nagao, MD, (Safety and Health Organization,
Chiba University, Japan) discussed practical problems in the
application of LD-CT screening in Japan. In Japan, more than
100,000 subjects received LD-CT scans as practice-based
opportunistic screening annually. These screenings are partly
supported by local governments or by insurance in Japan. He
addressed five major issues: reducing cost to the individual
for screening, increasing subsidies from local governments,
expanding the training of specialists for LD-CT reading,
application of computer-aided diagnosis (CAD), and qualifi-
cation of hospitals that had specialists to perform further
examinations and treatment for small lung cancers detected in
screening.
Tomotaka Sobue, MD, (Research Center for Cancer
Prevention and Screening, National Cancer Center Tokyo)
presented the historical background of lung cancer screening
in Japan. The lung cancer screening system has been devel-
oped based on well-established mass screening system for
tuberculosis, which had been in operation since 1951 and
continued in the 1970s and 1980s. In 1987, lung cancer
screening using chest radiographs (and sputum cytology for
high-risk populations) for people aged 40 years or older was
introduced as a national policy under the Health Services Law
for Aged. This decision was not based on direct evidence of
a benefit from lung cancer screening in terms of a reduction
of mortality. Since 1992, six case-controlled studies from
different large groups of Japanese have been published.
Although they were retrospectively analyzed, all studies in-
dicated beneficial effects, and four studies showed statisti-
cally significant mortality reductions of lung cancer. There is
no evidence that the difference between the trend of incidence
and mortality of lung cancer has been widened in Japan, and
the facts indicate that lung cancer screening in Japan has not
been effective at a national level. However, in the areas in
which these studies were conducted, lung cancer mortality
among women aged 50 to 74 years has been decreasing. Lung
cancer screening using chest radiographs and sputum cytol-
ogy is effective only when it is applied with high quality
assurance, and many of the systems in Japan have not reached
this level.
Hironobu Ohmatsu, MD, (National Cancer Center East
Hospital, Japan) presented the 10 year-experience of LD-CT
screening in the ALCA project in Tokyo. ALCA is a for-
profit organization to screen dues-paying members (smokers
aged 40 years or older) for lung cancer that was established in
1975 by Shigeto Ikeda, MD, who had was the first to develop
flexible bronchofiberscopy. In 1993, LD-CT was introduced
as a screening device at ALCA. Multi-detector CT (four
rows) has been used since 2002. Using 15 mAs of radiation
exposure, the data were acquired with 2-mm collimation and
10-mm reconstruction. From 1993 to 2004, a total of 18,331
FIGURE 1. (A) “Kagamibiraki,” Opening a Japanese sake
barrel head at the reception (the Garden of Nara-Ken New
Public Hall). (B) A wooden cup for Japanese sake printing
10 mm. It is challenging to detect nodules 10 mm in
diameter, that is, “curable lung cancer.”
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screenings have been performed, and 76 lung cancers
(0.44%) have been detected. Compared with historical data,
the ALCA detection rate was 3 times higher than that of
screening with a chest radiograph. Ninety two percent of the
cancers were peripheral type, and 62% were adenocarcinoma.
Mean tumor size was 17 mm, and 80% were stage I (74%
stage IA). The 5-year survival rate was 80.4%. In terms of
stage shift in patients with invasive adenocarcinoma, results
showed statistically significant shifts to early stage (stage I)
among the detected lung cancers during long-term repeated
LD-CT screening for more than 10 years. In other histology,
no statistically significant stage shift was seen.
James Jett, MD, (Mayo Clinic, USA) summarized the
final results of the Mayo trial on LD-CT screening. A total of
1520 high-risk participants aged 50 years or older were
enrolled and received five scans for 4 years. Non-calcified
nodules were detected in 51% of participants at the baseline
screening and in 73.6% after the fifth annual screening. Of the
non-calcified nodules, 61% were 4 mm or smaller in diame-
ter. Lung cancer was detected in 66 participants with 68
lesions. Sixty-five percent of prevalent and 62% of incidence
cancers were stage IA. Ten participants (18%) underwent
surgical procedures for benign nodules that had been detected
by screening. Screening high-risk individuals with LD-CT
detected early-stage lung cancer but also detected a large
number of non-calcified nodules that required periodic fol-
low-up scans.
Toru Nakagawa, MD, (Hitachi Health Care Center,
Japan) presented the 6-year experience on LD-CT screening
at the Hitachi Electric Co. Ltd. Among 12,645 individuals, 60
lung cancers were surgically diagnosed (0.47%). Of these
tumors, 90% were pathologically stage I. Annual repeat
screening was performed for 24,889 subjects, and 22 lung
cancers were detected. The detection rate was 0.09%, and all
were pathologically stage I. Dr. Nakagawa stressed that
repeat screening for the same cohort would be a powerful tool
with which to study the efficacy of a screening method like
LD-CT (Figure 2).
There were two other presentations on screening-re-
lated studies: one was biomarker analysis of the aggressive-
ness of CT screen-diagnosed tumors by Luis Montuenga,
MD, (Clinica Universitaria de Navara, Spain); the other was
competing causes of death in a lung cancer screening cohort
by Rowena Yip, MPH (Weil Medical College of Cornell
University, New York, NY).
ORAL PRESENTATIONS: TWO LARGE COHORT
STUDIES FOR LD-CT SCREENING
Tomio Nakayama, MD, PhD, (Osaka Medical Center
for Cancer and Cardiovascular Diseases, Japan) presented an
interim analysis of a nationally based cohort study on LD-CT
screening from the JLCSS group. This is a non-concurrent
cohort study with a control arm of participants receiving a
chest radiograph. Eligible subjects were aged more than 40
years and were never screened by LD-CT, excluding patients
who had been diagnosed with or were thought to have lung
cancer. The subjects who received LD-CT or a chest radio-
graph as screening from 1995 to 2002 were enrolled. The
study began in 2001, and the final analysis will be performed
in 2007. The sample size is an estimated 40,000 subjects for
the LD-CT cohort and 80,000 subjects for the usual chest
radiograph screening cohort to detect a 30% reduction of lung
cancer mortality where the effect of usual screening is 30%
and the pure effect of LD-CT screening is 51% (  0.05,
  0.2 two-sided test). The age of both groups is 40 to 74
years old, and follow-up period is 5 years. From nine screen-
ing groups in different districts of Japan, a total of 46,733
subjects were enrolled as the LD-CT group and 91,970 subjects
as a control group. In six screening groups, the subjects were
enrolled as a community-based screening and included a
large number of female nonsmokers (Table 1). The detection
rate of lung cancer in the LD-CT group was 0.69% in men
and 0.64% in women: 3.6 and 9 times higher than those of the
chest radiograph group, respectively. In repeated screenings,
detection rates in the LD-CT group decreased to 0.08%. The
rate of stage IA screen-detected lung cancers was 83% and
91% in baseline and repeated screenings, respectively. Cur-
rently, 850 deaths from all causes have been identified in the
LD-CT screening group versus 3480 deaths in chest radio-
graph group, compared with 85 lung cancer deaths in the
former group and 336 deaths in the latter group. In prelimi-
nary analysis, the discrepancy between overall mortality and
lung cancer mortality of the cohort became gradually larger in
men; however, it was not statistically significant (Figures 3).
FIGURE 2. Toru Nakagawa, MD (Hitachi Health Care Cen-
ter). Changes of the detection rate of lung cancer at the
baseline screening and repeat screenings.
TABLE 1. Performance of Lung Cancer Screening in JLCSS
CT screening cohort Usual screening cohort
Male Female Male Female
Detected lung cancer (n) 216 112 64a 36a
Detection rate (%) 0.73 0.65 0.19* 0.07†
From the presentation by Tomio Nakayama, MD. CT, computed tomography;
WHO, World Health Organization. a Lung cancer cases of the usual screening cohort
are not applicable. *P  0.05. †P  0.001.
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Data with the lung cancer-specific mortality rates for
each cohort, together with all caused mortality, will be
presented as a final analysis in 2007. As a subset analysis, a
significant difference in survival among subjects with LD-
CT–detected lung cancer was found depending on the tumor
size. Subjects with tumors smaller than 1 cm had better
survival than others, and subjects with tumors larger than 3
cm had the lowest survival rate.
Claudia Henschke, MD, PhD, (Weil Medical College,
Cornell University) reported the summarized data of the
6-year I-ELCAP project.
The ELCAP approach consists with two parts. Part A is
a diagnostic mission, whereas Part B is a prognostic mission.
In Part A, lung cancer distribution, such as stage, size, etc.,
will be clarified using the data obtained from baseline and
annual repeat screenings. In Part B, the fatality rates of
patients with screen-detected lung cancer, treated or non-
treated/delayed treatment will be clarified specific to stage
and size.
The mission of I-ELCAP is to advance policy-relevant
research on the early diagnosis of lung cancer and to foster
translation of up-to-date evidence into guidelines for practice.
The advantage of the I-ELCAP research approach is multi-
faceted. It should further state-of-the-art screening research
and clinical practice, it should provide for continual updating
in light of advancing knowledge, and result in incorporation
of technologic advances as they develop. I-ELCAP has ac-
cumulated 28,689 baseline CT screenings and 20,706 annual
repeat CT screenings at 38 institutions throughout the world.
Under the systematic protocol, 253 lung cancers and 31 lung
caners have been diagnosed at the baseline screening and
annual repeat screening, respectively.
The median diameter of screen-diagnosed lung cancer
was 15 and 8 mm in baseline and repeat screening, respec-
tively. More than 80% of screen-detected lung cancers were
stage I. A diagnostic performance biopsy proved malignancy
in more than 90% of patients. Non-solid type tumors showed
no size-stage relationship, whereas solid and semi-solid type
tumors did. I-ELCAP revises the protocol considering these
results and continues to accumulate new subjects and follow-
up.
Curability can be calculated as fatality rate (FR) of
untreated minus FR of treated divided by FR of untreated. In
x-ray screening, the curability of stage I x-ray screen-diag-
nosed cancers is estimated to be 67%. According to the SEER
database, curability of stage I lung cancers is estimated to be
71% in tumors 15 mm or smaller in diameter and 67% in
those 16 to 25 mm in diameter. Curability of screen-detected
stage I lung cancer in CT screening is estimated to be 97% if
the tumor is a solid nodular type. The percentage of deaths
that can be prevented by CT screening is estimated to be 81%
(95% CI, 75–87%), whereas deaths prevented by chest x-ray
screening is estimated to be 20% and, for those receiving
normal care in America, is estimated to be only 5%, accord-
ing to the 2005 report from the American Cancer Society.
Using the results of I-ELCAP, one can estimate a risk
assessment model and the values for decision making regard-
ing CT screening. For instance, a 55-year-old man who
smokes more than 30 pack-years has a probability of detec-
tion of stage I lung cancer by CT screening of approximately
80%.
General discussion focused on estimation of overdiag-
nosis as 10% in LD-CT screening, especially involving lo-
calized pure ground-glass opacity or non-solid nodules in
female nonsmokers, and the necessity of risk-benefit assess-
ment of LD-CT screening. In the case of lung cancer showing
solid or part-solid nodules on CT images, the ratio of over-
diagnosis may be small. Additional data on the natural course
of non-solid nodules should be accumulated.
ORAL PRESENTATIONS: EARLY DIAGNOSIS
Masahiro Kaneko, MD, (National Cancer Center Hos-
pital, Tokyo, Japan), reviewed the history of CT and dis-
cussed future progress of CT equipment and diagnostic sys-
tems for screening. He stressed rapid advance in software
development of CAD and characterization in the field of
LD-CT screening. Screening systems applicable to both pe-
ripheral and hilar lesions using rapidly reconstructed LD-CT
images will be desirable. Less invasive and more accurate
FIGURE 3. Tomio Nakayama, MD. A, Survival of patients
with LD-CT–screened lung cancers by size (JLCSS). B, Sur-
vival of patients with LD-CT–screened lung cancers by cycles
of screening (JLCSS).
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diagnostic intervention for LD-CT–detected nodules should
be developed. Virtual bronchoscopy and three-dimensional
reconstructed CT images will be potentially useful in per-
forming accurate bronchoscopic biopsy of small peripheral
lesions detected by using LD-CT screening, Progress in
automated diagnostic support using CAD is mandatory for
LD-CT screening.
Takashi Terauchi, MD, (Research Center for Cancer
Prevention and Screening, National Cancer Center Hospital,
Tokyo, Japan) discussed difficulties in using 2-[18F]fluro-2-
deoxy-D-glucose (FDG)-positron emission tomography
(FDG-PET) scan for cancer screening. In Japan, more than 60
groups introduced FDG-PET as their daily practice-based
opportunistic screening. FDG-PET is a convenient tool for
whole-body screening to detect malignancy, but its accuracy
is influenced by many factors, such as the size and biological
behavior of tumor and the diabetic state of the subject.
FDG-PET is not currently justified as a tool of cancer screen-
ing. Dr. Terauchi commented that the detection rate of cancer
was up to 5% in his preliminary whole-body screening
project for 3000 subjects 50 years of age or older, conducted
with the approval of the institutional review board of the
National Cancer Center in Tokyo. He will continue with
follow-up on the same cohort for 10 years with multimodality
repeated screening protocol.
Masami Sato, MD, (Miyagi Cancer Center, Japan),
presented the results of population-based screening with chest
radiograph and sputum cytology, which was conducted in the
Miyagi prefecture in the 1990s. They applied an improved
method for staining sputum samples from high-risk groups.
He stressed the importance of sputum cytology for high-risk
groups because the rate of Japanese smokers is still high: 42%
of men and 10% of women for the overall population, and
56% and 20%, respectively, in the younger generation. How-
ever, there has been a decrease in the number of hilar-type
lung cancers. He added that overdiagnosis of occult hilar-type
lung cancers was very rare, according the long-term fol-
low-up data from this group.
David Carbone, MD, PhD, (Vanderbilt University) dis-
cussed the identification and application of molecular signa-
tures to the diagnosis and treatment for lung cancer. Using
matrix-assisted laser desorption/ionization mass spectros-
copy, tumor-specific proteins were characterized with small
tumor samples. In his proteomics study, 57 proteins were
characterized for the discrimination of malignant phenotypes
with a sensitivity of 66% and specificity of 99%. Proteomics
show useful information as response and prognostic indica-
tors for patients with lung cancer. Studies on the relationship
between proteomics and response/resistance to molecular-
targeted drugs such as epidermal growth factor receptor and
thyrosine kinase inhibitors are advancing. Proteomic patterns
obtained directly from serum of nanogram amounts of fresh
frozen human lung tumor tissue may allow the classification
and prediction of histological groups, as well as nodal in-
volvement and survival in resected non-small cell lung can-
cer. He displayed a map of whole-body protein analysis
showing organ-specific patterns of protein distribution with
array-like display of peaks of mass spectroscopy.
Kiyoshi Yanagisawa, MD, PhD, (Nagoya University,
Japan) presented protein expression profiles in non-small cell
lung cancer, on which he is working with Dr. David Carbone.
They were able to obtain more than 2600 mass spectroscopy
peaks from histologically selected regions of single frozen
sections from 174 resected human non-small cell lung cancer
and 27 normal lung tissues. They found 15 protein patterns as
prognostic indicators of non-small cell lung cancer. In pre-
liminary studies, proteomics has been shown to discriminate
malignant from benign lesions using serum samples. Cur-
rently, they have identified dozens of molecular marker
proteins of interest using reverse-phase high liquid chroma-
tography followed by sequencing of peptides with an liquid
chromatography tandem mass spectroscopy instrument. With
further progress of proteomics research, Dr. Yanagisawa
mentioned the possibility of identifying each target protein
and characterizing the risk factors for specific subgroups and
applying early detection of lung cancer in each molecularly
characterized subgroup.
SURGICAL TREATMENT FOR SMALL LUNG
CANCER
Kenji Suzuki, MD, (National Cancer Center Hospital,
Tokyo) presented a prospective study for peripheral lung
cancers 2 cm or smaller in diameter. His group chose a
surgical procedure depending on findings of thin-section
high-resolution (TSHR) CT images. The CT findings were
classified as non-solid, part-solid, semi-consolidation, and
solid depending on the ratio of the area of ground-glass
opacity lesions on TSHR CT images. The end point of this
study was local recurrence and prognosis. From 1998 to
2004, they performed surgery in 274 cases with ground-glass
opacity features. They had a reference protocol by which a
patient with a non-solid lesion 1.5 cm or larger in diameter
would immediately undergo surgery; otherwise, patients
would be monitored with TSHR CT every 3 months. Eighty-
eight patients showed pure ground-glass opacity or non-solid
lesions on TSHR CT images. Of these, 53 patients were
female, and the median age was 63 years. Among the 54
lesions smaller than 1 cm, only one increased in size; another
one disappeared and the others were stable. Among the 35
lesions 1 cm or larger in diameter, 43% increased in size or
changed in density. Of the patients, 10% had a history of lung
cancer, and most had tumors that increased in size, which
indicates that those lesions might be metastases instead of
double primary cancer. Examination of the surgical margin
would not be meaningful in case of non-solid lesions; his-
topathological diagnosis of invasiveness seemed more impor-
tant for these lesions. Lung cancers showing ground-glass
opacity features on high-resolution CT images tend to have a
less invasive nature. Limited surgical resection might be
suitable for selected patients.
Ken Kodama, MD, (Osaka Medical Center for Cancer
and Cardiovascular Diseases, Japan) presented the results of
a prospective phase II study evaluating alternatives to resec-
tion as early intervention for small peripheral lung cancer
from a single institute. Eligible patients exhibited peripheral
lung cancer with c-T1N0M0 with primary lesions 2 cm or
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smaller in diameter. The percentage of ground-glass opacity
area on high-resolution CT images (50% as a cutoff value)
was applied as a new indicator for selection of a surgical
procedure. From 1997 to 2004, 179 patients were enrolled in
this study. Preoperative factors such as size, location, and
percentage of the ground-glass opacity area on the HRCT
were used as additional indicators for determining the type of
lung resection (wide wedge resection, segmentectomy, or
lobectomy). Other indicators from high-resolution CT find-
ings (percentage of ground-glass opacity in tumor and intra-
operative lavage cytology of the resection margin) were also
considered when making decisions regarding surgical proce-
dure. He concluded that this management algorithm seems to
be feasible for preventing both local recurrence and excessive
resection of normal lungs.
Nasser Altorki, MD, (Weil Medical College of Cornell
University, New York, NY) summarized the results from 333
patients who underwent surgery in 35 institutes as a cooper-
ative study of the I-ELCAP. More than 50% were female, and
63% had tumors smaller than 1.5 cm in diameter. Histolog-
ically, 65% were adenocarcinoma and more than 80% were
pathologically stage IA. Less than 5% and 8% of patients
had pathologically N1 and N2 diseases, respectively. Of the
patients, 10% showed multiple lesions. One third of the
patients had non-solid or part-solid lesions, most of which
were 1.5 cm or smaller in diameter.
NON-SURGICAL TREATMENT
Fumio Imamura, MD, (Osaka Medical Center for Can-
cer and Cardiovascular Diseases, Japan) presented their ex-
perience of brachytherapy for peripheral lesions through 21G
percutaneous needles through applicators using 192Ir. They
had 12 patients and irradiation of 20 Gy/fraction (Gy/fr) in all
percutaneous brachytherapy. The schedule was gradually
hypofractinated 5 Gy/fr for five times to 12.5 Gy/fr for two
times in transbronchial brachytherapy. The local control rate
was up to 88%, and the estimated 5-year survival of these
patients was more than 60%. Brachytherapy in both routes
was feasible, with mild adverse reaction, such as focal radi-
ation pneumonitis and one mild pneumothorax. Dr. Imamura
discussed his experience of conformal radiation therapy
among 43 patients with T1-T4N0M0 lung cancer for 4 years
in a single institute. It was not a randomized controlled trial,
but the patients’ response to conformal irradiation was com-
parable to those with brachytherapy, but the former resulted
in severe radiation pneumonitis in some patients. Although
the application of brachytherapy for lung cancer is still
limited, it may be a treatment of choice for selected periph-
erally located C-T1N0M0 lung cancer.
Peter Littrup, MD, (Karamanos Cancer Institute) pre-
sented his experience of the treatment of peripheral lung
tumors, including metastatic nodules, using percutaneous
microwave and radiofrequency ablation. Three probes cover
a larger lesion without intolerable complications. Pneumo-
thorax occurred in 36% of subjects, but only 12% required
tube drainage. He also discussed the application of cryosur-
gery for peripheral tumors. Although the exact mechanism of
local control achieved with cryosurgery has not been eluci-
dated, this method seems to be less painful and relatively safe
for a nodule adjacent to a large vessel; therefore, it has the
potential for use without major complications. However,
further study and longer follow-up of treated patients are
needed for this technique to become more widely available.
Masafumi Kawamura, MD, (Keio University, Japan)
summarized the results of treatment for metastatic pulmonary
nodules using cryoablation under local anesthesia. With a
percutaneous approach through CT-guided needles, two to
three cycles of cryosurgery were effective in treating meta-
static nodules. Histologically, the structure of pulmonary
parenchyma was preserved after cryosurgery in animal ex-
periments. Cryosurgery could avoid fatal vascular hemor-
rhage with modulation of depth and direction of inserted
probes. It might be achievable to treat lesions in segmental
bronchus. In Dr. Kawamura’s phase II study, eligibility
factors were five or fewer metastatic lung tumors smaller than
3 cm in diameter and performance status of 0 or 1 without
metastasis in other organs. Among 20 patients, nine had two
or more nodules, and the local control rate was greater than
80%. Mild pneumothorax, pleural effusion, and hemoptysis
were transient complications. One patient had irreversible
phrenic nerve palsy, and one had tumor implantation. Dr.
Kawamura summarized that percutaneous transthoracic
cryoablation with local anesthesia seemed to be feasible and
that the best candidates for this method would be patients
with nodules smaller than 3 cm in diameter without other
metastases in other organs.
Masayuki Baba, MD, (Research Center Hospital for
Charged Particle Therapy, National Institute of Radiological
Science, Japan) presented the results of clinical trials for
patients with stage I peripheral non-small cell lung cancer
using charged heavy particles (carbon ion radiotherapy).
From 1994 to 1999, this group conducted a phase I/II trial for
stage I non-small cell lung cancer using carbon ion radiation
monotherapy. An optimal dose of 90 GyE in 18 fractions over
6 weeks and 72 GyE in nine fraction over 3 weeks were
tolerable and achieved 95% local control with minimal pul-
monary damage. In the successive phase II study, 129 pa-
tients with 131 lesions received this treatment from 1999 to
2004. Two third of the nodules were adenocarcinoma, and 72
lesions were 3 cm or smaller in diameter. Using four portals,
this group studied feasibility of different fractions. They
applied 72 GyE in nine fractions over 3 weeks, or 52.8 GyE
for stage IA and 60 GyE for stage IB over 1 week. A
respiratory-gated irradiation system was used in each patient.
The local control rate was 92% in adenocarcinoma and 78%
in squamous cell carcinoma. The 5-year survival rate was
54.7% and 46.1% in T1 and T2, respectively. Adverse reac-
tions were tolerable, and carbon ion radiation therapy is
considered a valid alternative to surgery for stage I non-small
cell lung cancer.
Minoru Uematsu, MD, (Keio University, Japan) pre-
sented CT-guided stereotactic radiation therapy without pa-
tient breath-holding. In his previous study, positioning error
of this method was shown to decrease to within 5 mm with
shallow breathing and oxygen support. From 1994 to 2004,
100 patients with stage I non-small cell lung cancer were
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treated using this method; half had tumors 3 cm or smaller in
diameter. Histologically, 67% were adenocarcinoma and 26%
were squamous cell carcinoma. Half were inoperable because
of poor organ function, and the rest did not elect to undergo
surgery. Radiation was 50 to 60 Gy in five to 10 fractions for
1 to 2 weeks. The 5-year survival rate was 50% in this study.
There was only one treatment-related death, a 70-year-old
man with squamous cell carcinoma of hilar-type and hemop-
tysis caused by bronchopulmonary fistula. Stereotactic focal
high-dose radiation therapy was feasible for stage I lung
cancer and has been covered by national insurance in Japan
since 2004. This group is trying to develop a beam chasing
system instead of gating to minimize movement of breathing
and concentrating the radiation beam to target the lesion.
Laurie Gasper, MD, (University of Colorado Health
Science Center) presented a summary of the I-ELCAP pa-
tients who were treated with radiation therapy. There were 29
patients (7% of all I-ELCAP patients) who underwent radi-
ation therapy. Half were female; the mean age was 70 years;
and mean smoking history was 45 pack-years. All received
radiation therapy because of poor organ function. The 2-year
disease-specific survival was 89%, and follow-up is continu-
ing. In her literature review, Dr. Gasper cited 2-year survival
rates of 30 to70% among patients with stage I or II non-small
cell lung cancer who received radiation therapy alone or a
combination of radiation and chemotherapy or surgery. Fur-
ther studies of radiation dose and effectiveness of combined
modalities are warranted.
PATHOLOGY
Masayuki Noguchi, MD, (Institute of Basic Science
Research, University of Tsukuba, Japan) summarized the
results of the consensus meeting for bronchioloalveolar car-
cinoma (BAC) that was held in New York, NY last year. The
definition of BAC is a noninvasive lesion-preserved elastic
frame of lung parenchyma. At the consensus panel, 10% of
test samples with pure BAC could be diagnosed in agree-
ment. Dr. Noguchi proposed that the World Health Organi-
zation histological subclassification of pulmonary adenocar-
cinoma should be revised as part of BAC. Pure BAC is a
noninvasive lesion and should be included as a preneoplastic
entity instead of adenocarcinoma. Most lesions that are part-
solid type on CT images were diagnosed as adenocarcinoma
mixed with BAC components. Radiological and pathological
correlation studies revealed that pure ground-glass opacity in
high-resolution CT images correspond to BAC features in
histology. The biological behavior of adenocarcinoma is
related to the ratio of the area of BAC (replacing the alveolar
epithelium) and the area of solid component (with fibroblasts
infiltration or with scar formation) in a lesion, which indicates
the ratio of ground-glass opacity radiologically. The correla-
tion between TSHR CT images and histology is shown in
Table 2. A pathologist can determine whether the lesion has
BAC components in a resected specimen, but it is difficult to
determine the ratio of BAC component in a whole lesion.
TSHR CT images will be able to visualize the ratio of
ground-glass opacity easily using a three-dimensional recon-
struction technique.
Adi Gazdar, MD, (University of Texas Southwestern
Medical Center) presented endothelial growth factor receptor
(EGFR) family mutations in the pathogenesis of lung cancer.
The mutation of TK domain of the EGFR targets specific
subpopulations of non-small cell lung cancer; that is, adeno-
caricnoma histology, non-smoker status, East Asian ethnicity,
and female gender. Gene amplification and amplification
mutation of other family members such as HER2, EGFR3,
and EGFR4, as well as downstream signaling pathway genes,
including k-RAS and b-RAF, may have important roles in the
evolution of adenocarcinoma. Mutations in EGFR and HER2
are the first known molecular changes that target lung cancers
arising in non-smokers. These mutations are found in both
peripheral adenocarcinoma and their precusor lesions atypical
adenomatous hyperplasia. They are absent in hilar-type ade-
nocarcinoma such as bronchial gland tumors. Mutations in
k-RAS and b-RAF have often been shown in adenocarcinoma
of smokers. The molecular pathways to lung cancers in
smokers and non-smokers may be different. The mutation
status of EGFR correlates partly to sensitivity and resistance
to EGFR TK inhibitors. Understanding the biological mech-
anism and role of these gene mutations will lead to the
improved selection of patients to treat effectively and to find
preventive interventions for the high-risk population for ad-
enocarcinoma of the lung.
TABLE 2. Correlation of Radiologic-Pathologic Findings with Small Peripheral Adenocarcinoma
WHO classification
Histologic classification of
small adeno-carcinoma* TSHR CT** findings
BAC type adenocarcinoma
Bronchioloalveolar carcinoma Type A and B Pure GGO
Mixed adenocarcinoma with BAC component Type C GGO with a solid component
Non-BAC type adenocarcinoma Solid nodule without GGO
Acinar Type E
Papillary Type F
Solid adenocarcinoma with mucin Type D
Mixed adenocarcinoma without BAC component Mixed type with D, E and F
* Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H, et al. Small adenocarcinoma of the lung: Histologic characteristics and prognosis. Cancer
1995; 75: 2844–52.
**TSHR CT  thin-section high-resolution CT.
Eguchi and Henschke Journal of Thoracic Oncology • Volume 1, Number 2, February 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer196
Yasushi Yantabe, MD, (Aich Cancer Center, Japan)
presented a new molecular classification for adenocarcinoma
of the lung through surgical-pathological molecular study in
his institute. Thyroid transcriptional factor-1 (TTF-1) is con-
sidered to be a key regulatory gene of normal peripheral lung
parenchyma regulating functional molecules such as surfac-
tant proteins. Dr. Yantabe addressed the concept of the
terminal respiratory unit (TRU) as a common lineage repre-
senting a functional unit of a normal peripheral airway. The
TTF-1–positive subtype of adenocarcinoma was found to be
prevalent in women and non-smokers, and it frequently
showed mutation of the EGFR. Furthermore, other molecular
alterations, such as p53, K-ras, Rb, and p27/Kip2, were
involved with a pattern different from other subtypes. This
TRU-type adenocarcinoma is a distinct entity in molecular
profiles. Adenocarcinoma from TRU showed better prognosis
compared with other types of adenocarcinoma in his series.
Lineage of TRU-adenocarcinoma includes atypical adenoma-
tous hyperplasia, non-mucinous BAC, adenocarcinoma with
a BAC component, and a proportion of poorly differentiated
adenocarcinoma. Clinically, patient selection based on the
molecular features may be useful for the diagnosis and
treatment of lung adenocarcinoma.
Selection mechanisms for k-Ras and EGFR mutation
depending on clinical factors such as smoking history, eth-
nicity (East Asian), and sex (female) were issued, and the
EGFR mutation in premalignancy or in other pulmonary
diseases was the focus of discussion.
In the poster session, there were 30 scientific presenta-
tions, including results and model assessment of LD-CT
screenings, computer-aided diagnosis for LD-CT, PET scan
for opportunistic screening, detection of coronary diseases on
LD-CT screening, diagnostic interventions for CT-detected
small nodules, local less-invasive treatment for CT-detected
lung cancer, pathological features of small lung cancers, and
the issues of overdiagnosis.
Small-group workshops focused on three topics: CT-
guided, fine-needle aspiration biopsy and follow-up issues
including algorithm of follow-up in negative biopsy; CAD
and characterization of non-calcified nodules in LD-CT
screening; and multicenter trials for LD-CT–detected small
lung cancer.
The final portion of the conference was three educa-
tional seminars focused on the interpretation of LD-CT im-
ages as a diagnostic tool for screening by Shusuke Sone, MD,
(Azumi General Hospital, Japan), Dorith Shaham, MD,
(Hadasssh Medical Center, Israel), and Salvatore Giunta,
MD, (Instituto Nazionale Tumori Regina Elena, Italy); man-
agement of small nodules detected in LD-CT screening by
David Yankelevitz, MD, (Weil Medical College of Cornell
University, New York, NY), Javier Zulueta, MD, (Clinica
Universitaria de Navarra, Spain), Kiyoshi Mori, MD,
(Tochigi Cancer Center, Japan), and Kozou Yamada, MD,
(Kanagawa Cancer Center, Japan); and computer assistance
in reading LD-CT images by Susan Wood, PhD, (Medicsight,
UK), Gerhard Kohl, (Siemens AG, Germany), and Noboru
Niki, PhD, (University of Tokushima, Japan).
We had an exciting and provocative conference in
Nara, Japan, with the cherry trees in full bloom. We will
make progress to the second stage of LD-CT screening and
accumulate innovative scientific evidence on the diagnosis
and treatment for early-stage, curable lung cancer.
Finally, we gratefully acknowledge the West Japan
Thoracic Oncology Group; Tokai University School of Med-
icine; Medicsight (UK); Siemens (Germany); Astrazeneka
(Japan); and other companies for their sponsorship of this
conference.
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